Home » Stocks » Outlook Therapeutics

Outlook Therapeutics, Inc. (OTLK)

Stock Price: $1.40 USD 0.06 (4.48%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 172.43M
Revenue (ttm) 6.44M
Net Income (ttm) -36.84M
Shares Out 123.17M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $1.40
Previous Close $1.34
Change ($) 0.06
Change (%) 4.48%
Day's Open 1.33
Day's Range 1.32 - 1.49
Day's Volume 5,732,773
52-Week Range 0.50 - 2.19

More Stats

Market Cap 172.43M
Enterprise Value 178.71M
Earnings Date (est) Dec 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 123.17M
Float 39.94M
EPS (basic) -1.42
EPS (diluted) -1.57
FCF / Share -0.63
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.14M
Short Ratio 0.69
Short % of Float 2.03%
Beta 0.36
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 26.79
PB Ratio n/a
Revenue 6.44M
Operating Income -33.28M
Net Income -36.84M
Free Cash Flow -30.14M
Net Cash -6.28M
Net Cash / Share -0.05
Gross Margin -243.25%
Operating Margin -517.04%
Profit Margin -789.10%
FCF Margin -468.20%
ROA -100.94%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.31*
(350.71% upside)
Low
3.25
Current: $1.40
High
9.00
Target: 6.31
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue8.153.093.812.985.229.05
Revenue Growth163.84%-18.99%27.92%-42.91%-42.33%-
Gross Profit8.153.093.812.985.229.05
Operating Income-36.30-29.64-35.88-51.35-46.56-12.39
Net Income-34.52-30.09-38.85-53.30-47.39-13.73
Shares Outstanding18.194.933.002.151.221.06
Earnings Per Share-1.98-9.74-14.40-29.36-43.44-19.44
Operating Cash Flow-32.29-33.04-15.51-45.48-27.48-7.02
Capital Expenditures-0.44-2.78-0.29-1.10-8.80-2.37
Free Cash Flow-32.73-35.82-15.80-46.58-36.28-9.39
Cash & Equivalents8.021.723.192.579.282.56
Total Debt11.3317.3213.804.1219.9615.17
Net Cash / Debt-3.32-15.60-10.62-1.55-10.68-12.61
Assets17.1322.2820.7325.4135.0111.60
Liabilities27.9043.0951.4630.5862.5632.05
Book Value-16.13-25.54-33.65-5.17-54.22-45.15
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Outlook Therapeutics, Inc.
Country United States
Employees 14
CEO Lawrence A. Kenyon

Stock Information

Ticker Symbol OTLK
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OTLK
IPO Date May 13, 2016

Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.